The Vector Core will play an integral and essential role in all subprojects. First, all of the Subprojects in this Program Project will require the availability of well characterized, high titer recombinant virus stocks. Isolation of such stocks is labor intensive and must be done in a manner that insures reproducible quality. Therefore, the primary mission of the Vector Core will be to generate the recombinant virus needed for the Subprojects in this Program. Two kinds of recombinant virus will be available, Adeno-associated virus (AAV) and Adenvirus. Each virus preparation will be purified by CsC1 centrifugation and will be titered by a method (infectious center assay, plaque assay) that will allow comparison to all other stocks regardless of the transgene or promoters used. In addition, quality control assays will be performed to assess the particle to infectivity ratio of each stock and the levels of wild type AAV or replication competent adenovirus contamination. This will involve the use of dot blot and PCR assays for adenovirus, AAV, and rAAV particles, as well as, infectious center assays and plaque assays for wild type AAV and adenovirus, respectively. The second goal of the Vector Core will be to develop improved methods for preparing rAAV stocks. These will focus inparticular on developing herpesvirus helper viruses carrying the AAV rep and cap genes which show promise of increasing the yield of rAAV virus preparations when used in conjunction with producer cell lines carrying rAAV proviruses. The third goal of the Vector Core will be to develop improved methods for construction of adenovirus recombinants using the Cre-Lox P vectors that can be assembled in vitro prior to the growth of recombinant adenovirus. Finally, the Vector Core will introduce methods for the growth of improved lentivirus vectors described in Subproject 4 (Chang) when they become available.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
1P50HL059412-01
Application #
6242869
Study Section
Project Start
1997-09-30
Project End
1998-08-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
1
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Florida
Department
Type
DUNS #
073130411
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Smith, Barbara K; Martin, A Daniel; Lawson, Lee Ann et al. (2017) Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: Clinical evidence of respiratory plasticity. Exp Neurol 287:216-224
Salganik, Maxim; Aydemir, Fikret; Nam, Hyun-Joo et al. (2014) Adeno-associated virus capsid proteins may play a role in transcription and second-strand synthesis of recombinant genomes. J Virol 88:1071-9
Elder, Melissa E; Nayak, Sushrusha; Collins, Shelley W et al. (2013) B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 163:847-54.e1
Qiu, Kai; Falk, Darin J; Reier, Paul J et al. (2012) Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice. Mol Ther 20:21-7
Wu, Ke; Li, Shoudong; Bodhinathan, Karthik et al. (2012) Enhanced expression of Pctk1, Tcf12 and Ccnd1 in hippocampus of rats: Impact on cognitive function, synaptic plasticity and pathology. Neurobiol Learn Mem 97:69-80
ElMallah, Mai K; Falk, Darin J; Lane, Michael A et al. (2012) Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9. Hum Gene Ther Methods 23:148-56
Salganik, Maxim; Venkatakrishnan, Balasubramanian; Bennett, Antonette et al. (2012) Evidence for pH-dependent protease activity in the adeno-associated virus capsid. J Virol 86:11877-85
Petrs-Silva, Hilda; Dinculescu, Astra; Li, Qiuhong et al. (2011) Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 19:293-301
DeRuisseau, Lara R; Fuller, David D; Qiu, Kai et al. (2009) Neural deficits contribute to respiratory insufficiency in Pompe disease. Proc Natl Acad Sci U S A 106:9419-24
Clément, Nathalie; Knop, David R; Byrne, Barry J (2009) Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies. Hum Gene Ther 20:796-806

Showing the most recent 10 out of 19 publications